Led by Jacques Ferreira, an RCVS and European Specialist in Veterinary Anaesthesia and Analgesia (pictured right), the new clinic will provide a bespoke pain management plan for pets referred both by external first opinion practices or internally by colleagues in other disciplines at the centre.
Jacques, who joined Willows in 2018 having previously lectured in Veterinary Anaesthesia at the University of Liverpool after specialising in the same subject in his native South Africa, said: "Just as with humans, our pets are living longer and, with that, there is an increased risk of developing chronic pain conditions.
"Traditionally, the most common patients are cats and dogs with chronic joint disease such as osteoarthritis but patients with a history of back problems and trapped nerves, cats with chronic cystitis and even those with some forms of cancer may benefit.
"We will work with first opinion vets who refer their patients to us, as well as internal referrals. The management of chronic pain is obviously ongoing but the aim for us would be to get to a stage where pain is effectively managed through the most appropriate avenue and check-ups are only needed every few months.
For more information, visit www.willows.uk.net.
The BSAVA says there has been a real resurgence in the number of people keeping backyard poultry for a self-sufficient supply of food and because they often become part of the family, owners have come to expect a standard of veterinary care akin to that available for their cat or dog. Yet many veterinary surgeons are unfamiliar with consulting on and treating these birds.
The BSAVA Manual of Backyard Poultry Medicine and Surgery has been written by an international selection of specialist authors. It covers everything from husbandry and basic clinical techniques to medical and surgical treatment of conditions, and more advanced practices such as endoscopy and post-mortem examination.
The manual covers chickens, turkeys, ducks, geese, guinea fowl, ornamental pheasants and peafowl. The BSAVA says it is hoped that the manual will make treating backyard poultry more interesting and rewarding, and therefore encourage more practitioners to see feathered patients.
One of the editors, Guy Poland said: "We are very proud of the valuable contributions made by all the authors to the manual. We hope that their hard work will provide a useful resource for veterinary practitioners unfamiliar with poultry medicine to deliver improved care for their patients and maybe inspire an interest that they develop further."
BSAVA Manual of Backyard Poultry Medicine and Surgery is available in a printed edition (£85; £55 to BSAVA members) and online edition (£70.83+VAT; £45.83+VAT to BSAVA members).
The authors say that whilst it has long been suspected that adverse drug reactions are under-reported, this study is the first to show the scale of the problem, using real data from veterinary clinical records.
For the study, researchers looked for electronic heath records within the Small Animal Veterinary Surveillance Network (SAVSNET) which contained “adverse drug reactions” and “side effects” in the free-text clinical narratives.
The results were then analysed to determine the suspected product, the seriousness and expectedness of the event, and whether the event had been reported to the Veterinary Medicines Directorate or Marketing Authorisation Holders.
Of the 827 cases of suspected adverse drug reactions identified out of a total of 10,565 records reviewed, approximately 90% were not reported.
74% were related to dogs and 70% were listed as “expected” (i.e. already listed in the product information).
The clinical severity of the reaction didn’t appear to impact whether it was reported.
Dr Heather Davies, lead author of the study, said: “As adverse drug reaction reporting rate is directly linked to the regulators ability to mitigate safety issues, this paper is a call to arms encouraging all veterinary professionals to report suspected adverse drug reactions and regulators to make reporting quicker and easier.
"It also the highlights the promise that big real-world data sets hold in enhancing drug safety monitoring processes.”
https://onlinelibrary.wiley.com/doi/full/10.1111/jsap.13721
The Disciplinary Committee heard three charges against Dr Jones.
The first and second charges were that, in March 2018, Dr Jones made signed entries in the passports and made corresponding entries in clinical records of four horses indicating that he had administered an influenza vaccination booster to each horse on 15 March 2018 and in relation to another horse a tetanus booster, when in fact he had administered the vaccination boosters on 21 March 2018, and that his conduct was misleading, dishonest and undermined the integrity of a vaccination process designed to promote animal welfare.
The third charge was that, on or around 21 March 2018, Dr Jones failed to make any entries in the clinical records for a horse in relation to an examination on 21 March 2018.
At the outset of the hearing Dr Jones admitted the facts in the first and second charges, and accepted that his actions were misleading, dishonest and that they undermined the integrity of a vaccination process. However, he disputed certain aspects of the written statements of the College’s witnesses. In particular he wanted his conduct to be taken in the context of the pressures that he was working under on that day, primarily that he was in a stressed state having had to euthanase a valuable stallion at the conclusion of his previous client appointment.
Dr Jones did not admit the third charge, explaining that he did not remember examining the horse on 21 March 2018 as alleged.
Based on Dr Jones' own admissions, the Committee found the first and second charges proven.
Regarding the third charge, the Committee heard evidence from the horse’s owner who said they were present during the examination taking place and the Committee was satisfied that the respondent did examine the horse on 21 March 2018 and that he had a duty to make a brief clinical note on the examination. As Dr Jones admitted that he made no such note, the Committee found the charge to have been proven to the requisite standard.
Having found the charges proven, the Committee then went on to consider whether or not Dr Jones’ proven conduct amounted to serious professional misconduct. The Committee, having considered the aggravating and mitigating factors, found that Dr Jones’ conduct as found proved in relation to both charges one and two, did constitute serious professional misconduct.
However, with regards to charge three, the Committee accepted that the respondent simply forgot that he had examined the horse and, therefore, the Committee was not satisfied that the failure to compile a record entry covering the horse’s examination constituted serious professional misconduct.
The Committee then considered what sanction to impose on Dr Jones in relation to the facts found proven in charges one and two. In doing so it took into account the 78 written testimonials and 4 character witnesses called on behalf of Dr Jones.
Ian Green, who chaired the Committee and spoke on its behalf, said: "The Committee’s decision on sanction has been based on an acceptance that the respondent’s conduct on this occasion was out-of-character, as the evidence of his character witnesses and the contents of the letters submitted in his support by his clients and other veterinary colleagues assert. The Committee also accepts that the respondent self-reported himself to his employer and to the College and has made a full and frank admission of his wrongdoing.
"Consideration was given to whether the sanction of a reprimand and/or warning as to future conduct would adequately reflect the gravity of the misconduct, however, after careful reflection it was concluded that such a sanction could not be justified. The reason is that acts of falsification involve acts of dishonesty by a professional person acting in a professional capacity, and the gravity of the matter arises not simply from the dishonesty but also from the possible consequences of the false certification. It should be clearly understood by members of the veterinary profession that, in appropriate false certification cases, the sanction of removal from the Register is one which may well be imposed."
The Committee therefore decided that suspending Dr Jones from the Register for two months would be the most appropriate sanction.
NOAH's third Brexit Barometer found that where in the last report, 17% of its members reported feeling 'very' or 'somewhat pessimistic', that figure has now risen to 32%.
Meanwhile, the National Audit Office has revealed in its 'Progress in Implementing EU Exit' report that Defra has been prevented from consulting with the veterinary market by DExEU.
The report states that Defra is one of the government departments most affected by EU Exit and looks in detail at four of Defra’s main workstreams, including ‘import of animals and animal products’ and ‘exports of animals and animal products’.
In an accompanying press release, the National Audit Office notes that in a no-deal scenario there will be a significant increase in certificates needing to be processed by veterinary surgeons. It says: "Without enough vets, consignments of food could be delayed at the border or prevented from leaving the UK. Defra intended to start engaging with the veterinary industry in April 2018, but has not been permitted to do so and now plans to launch an emergency recruitment campaign in October to at least meet minimum levels of vets required. It plans to meet any remaining gaps through the use of non-veterinarians to check records and processes that do not require veterinary judgement."
The BVA says it has previously outlined concerns about the potential for diluting veterinary certification, and is calling on the Government to fully engage with the veterinary profession before making any changes that could impact the UK’s ability to trade animal products safely and in line with high animal welfare standards.
The RCVS has also weighed in. Amanda Boag, RCVS President, said: "We are glad to see the National Audit Office report recognises that a ‘no deal’ Brexit scenario would be likely to reduce the supply of EU veterinary surgeons to the UK and cause uncertainty regarding the status of those EU veterinary surgeons who are currently living and working in the UK and that this would have a particularly serious impact on necessary veterinary work in public health and certification.
"We continue to engage with Defra and, like the BVA, we want to emphasise the essential need for Government to consult with the profession to ensure their plans meet requirements, including maintenance of the high veterinary standards for which the UK is known. We also want to highlight the importance and value of the veterinary profession in other areas of society including caring for pets, horses and farm animals as well as research, education and industry, and emphasise the impact of workforce shortages on all sectors."
Clive Elwood, Ian Battersby, Laurent Garosi, Nat Whitley and David Gould have all become Fellows for Meritorious Contributions to Clinical Practice. Meanwhile, Jerry Davies, founder of Davies Veterinary Specialists, has become a Fellow for Meritorious Contributions to the Profession.
Royal Canin highlights that obesity is one of the most common diseases that veterinary professionals face, and impacts patients' quality of life1, as well as their life expectancy2,3. Compliance is a common challenge in weight loss and even those that successfully reach their ideal weight frequently regain weight later. It therefore makes sense, says the company, to focus on prevention as well as long term management for obese cats and dogs.
Caroline Burke, Royal Canin UK Weight Management Specialist said: "Obesity is one of the most common diseases that vets and nurses see in practice, and this webinar is the latest in our programme of education around weight management. Vets and nurses will have the opportunity to learn about how they can help prevent, as well as manage obesity in practice, allowing them to truly make a difference to the lives of their patients."
Alex added: "Obesity is an ever-growing issue for cats and dogs, understanding the risks and prevention techniques is paramount for both pet owners and industry experts.
"This webinar aims to suggest how a lifelong practice monitoring programme can be implemented for the prevention of obesity. Whilst also reviewing the outcomes of weight management and defining types of prevention techniques which can be implemented."
To register for the webinar, 'How to be proactive rather than reactive for effective, preventative obesity management’, visit: https://vetportal.royalcanin.co.uk/cpd/webinar/
References
Neurodiversity Celebration Week is a worldwide initiative that challenges stereotypes and misconceptions about neurological differences, and the neurodiversity resource hub (www.vetmindmatters.org/resources/) aims to help members of the veterinary professions better understand how, for over one million people in the UK, neurological differences mean they learn and think in a way that is different to what is considered ‘neurotypical’.
Among the resources contained in the hub is information about neurological conditions closely associated with neurodivergence such as attention deficit hyperactivity disorder (ADHD), autism, dyspraxia and dyslexia, as well as information for employers about neurodiversity, including inclusive working tools and sources of government support.
A new ‘kite’ with six new modules are also being added to the MMI Kite App – a specialist microlearning platform for topics related to veterinary wellbeing – that deal specifically with issues related to neurodiversity. The six modules cover: what is neurodiversity; the importance of talking about neurodiversity; different types of neurodiversity; bespoke considerations for neurodivergent individuals; how neurodivergence can lead to innovation through thinking differently; and, exploring further how different brains work and how we can make our brains work best for us.
The College is also publishing a blog on the resource website by Dr Kirstie Pickles, Clinical Assistant Professor in Equine Medicine at the University of Nottingham, about her current MMI-funded research investigating the various workplace stressors that affect autistic veterinary professionals and what adjustments can be introduced to mitigate these stressors.
Lastly, at BSAVA Congress on Saturday 26 March between 3pm and 4pm, the RCVS has organised a discussion session on neurodiversity.
The discussion will be led by Roxanne Hobbs, a consultant in workplace inclusion particularly around neurodiversity, and will look at how to nurture and cultivate neurodiversity in the veterinary professions.
Lisa Quigley, Mind Matters Manager, said: “As a project focused on the mental health and wellbeing of veterinary professionals, the Mind Matters project has a commitment to recognising and providing a space for all forms of diversity, and so we are very glad to be supporting Neurodiversity Celebration Week again this year.
“We hope that our neurodiversity resource hub and our other initiatives during Neurodiversity Celebration Week will be useful source of information for everyone and will aid people in understanding neurodivergence, how it can manifest and how it can be supported in the workplace and educational settings.”
The Kennel Club has announced that the Crufts Best of Breed (BOB) winners in two of the high profile breeds - the bulldog and the Pekingese - failed their veterinary checks, so the breeds were not represented in the utility and toy group judging.
The British Veterinary Association says it welcomed the Kennel Club's initiative to put the veterinary checks in place for the BOB winner in the 15 high profile breeds at all championship dog shows starting at Crufts this year.
The 15 breeds have been identified as having particular health problems often due to poor conformation as a result of having been bred with exaggerated characteristics. The veterinary checks ensure the BOB winners are not suffering as a result of their conformation, such as eye problems, skin disease, lameness or breathing difficulties, which should have been identified by the judge.
Carl Padgett, President of the BVA, said: "Breeding dogs with exaggerated features must be tackled robustly. The veterinary checks are sending out a strong message that dogs with health problems will not win in the show ring, and only visibly healthy dogs will be rewarded.
"Dog showing can be a force for good for dog breeding and education but the veterinary checks on the first two groups at Crufts have highlighted the health problems that all too often affect man's best friend.
"We hope this strong action by the Kennel Club will be a wake-up call to those breeders and judges that still need to embrace the message that health should always be at the top of the agenda."
In a statement given to the Veterinary Record earlier this year, the College said:
"In 2017, our commitment to equality for our LGBTQ+ employees, members of the professions and other stakeholders, was cemented when we became a Stonewall Diversity Champion, with the aim of ensuring that all people in the community are accepted, without exception, within the veterinary professions.
In subsequent years this commitment has been demonstrated by the establishment of our Diversity & Inclusion Group, for which LGBTQ+ representation is a key component and has been incorporated into both our internal and external diversity and inclusion strategies.
Focusing on our internal diversity and inclusion strategy, the insight from Stonewall and our internal LGBTQ+ group, has aimed to make the RCVS a safe space for people from the LGBTQ+ community by creating a fully inclusive workplace.
These insights have also fed into the profession-facing work of the Diversity & Inclusion Group and its strategy.
After six years as a Stonewall Diversity Champion, we have decided this year not to renew our contract with the organisation, on the basis that we feel we no longer need to work with an external organisation to continue to deliver on our commitment to equality, diversity and inclusion.
The RCVS will continue to demonstrate allyship and be a safe space for all groups within the LGBTQ+ community, as demonstrated by the fact we are creating a staff network representing RCVS colleagues from marginalised communities.
We may in future decide to work with another accredited organisation, but until the staff network is in place, no decisions have been made. For example, we have recently brought in a staff policy regarding how best to support RCVS employees who are going through the process of gender reassignment, reiterating the current legal position, how to report experiencing or witnessing transphobic discrimination, as well as advice for colleagues supporting those undergoing gender reassignment and those who have family members going through the process. We are grateful for Stonewall for working with us over the past six years and helping us, through its Workplace Equality Index, to finesse our policies and procedures in relation to LGBTQ+ rights and issues and drive forward our agenda to be a diverse and inclusive workplace and regulator."
Virbac has launched a new 12 month version of Suprelorin, the reversible medical castration implant for dogs, widening the options for clients seeking an alternative to surgical castration.
Product manager Chris Geddes MRCVS said: "The launch of Suprelorin 12 gives practices the chance to offer dog owners a more convenient castration option. The implant renewal can now be included with their dog's annual boosters or health check.
"The slow-release implant is inserted at the back of the neck in the same manner as a microchip. There is no anaesthetic, no surgery and no scarring. The current implant, which contains 4.7mg active and lasts for around 6 months after insertion, will continue to be available for those wanting a more brief solution or as a trial.
"Deslorelin is a GnRH superagonist which causes suppression of LH/FSH, and therefore testosterone production, leading to temporary infertility."
For further information on Suprelorin/12, please call and ask to speak to one of our veterinary advisors on 01359 243243, or contact your local Virbac territory manager.
Bayer Animal Health has launched Remend Wound Spray Gel for cats, dogs and horses.
The new gel contains Remend's structurally modified hyaluronic acid (HA). Bayer says it provides a matrix for cellular events that occur during the proliferative phase of the healing process, which has been shown to enhance healing1, and can promote rapid wound closure
Georgie Hollis BSc from www.vetwoundlibrary.com said: "Managing wounds can be challenging in veterinary practice; the progression of wound healing can be influenced by many factors, and selecting an appropriate product to apply should be based on the needs of the individual wound. A product that provides a moist healing environment and support of the proliferative phase ensures that cellular activity is optimised, helping to improve healing times and minimise scar tissue."
Bayer says Remend Wound Spray Gel is designed for use as part of the overall management of wounds; additional measures such as lavage, debridement and control of infection are equally important, as is giving consideration to any secondary factors that may delay healing if not addressed. The product aims to achieve greater compliance amongst owners by providing an effective management option that is easy to apply. A single application may be sufficient to enhance wound closure in fresh uncomplicated wounds; however more complex wounds may require multiple applications in order to accelerate closure.
For more information, visit: www.vetcentre.bayer.co.uk
Currently Principal of the Royal Veterinary College, University of London, and previously Dean of the University of Glasgow’s School Of Veterinary Medicine, Stuart has been a member of RCVS Council since 2005, and served as RCVS President in 2014-15.
As chair of the Education Policy and Specialisation Committee in 2011, Stuart oversaw the College’s review of veterinary specialisation, which also led to the new Advanced Practitioner status.
He has also been a driving force behind the joint RCVS and BVA Vet Futures project since its inception in 2015.
As Chair of the RCVS Governance Panel, he recently saw through reform of the College’s governance arrangements to improve the efficiency and accountability of its decision-making processes.
Stuart has also chaired the RCVS Science Advisory Panel.
He continues to chair the College’s Mind Matters Initiative, which aims to improve the mental health and wellbeing of all those in the veterinary team.
A particularly notable achievement during his Presidential year was to allow UK veterinary surgeons to use the courtesy title ‘Doctor’ if they so wished.
Lizzie Lockett, RCVS Chief Executive said: "We have been incredibly fortunate to have someone of Stuart’s calibre, character and international renown on our Council for so many years. His contributions and commitment to the RCVS, as well as to the wider veterinary professions, are as significant as they are often understated.
"On behalf of RCVS Council and all the staff, I should like to say how delighted we are that he has been honoured in this way. Such recognition is very much deserved and we send him our warmest congratulations."
The Ear Protector sits on the back of the head and hooks onto face mask strings, pulling them backwards and away from the ears, thereby relieving pressure and stopping chafing.
The product was designed by AMufacture's Chief Operating Officer, William Howden, a former Olympic sailor who competed in the 2008 Summer Olympics in Beijing. He said: "Early in the pandemic, it became apparent to us that there was a serious need to address an unresolved problem with face masks – people were really beginning to suffer and were getting distracted from their work."
The Ear Protector is sterilisable in a dishwasher. It is also recyclable when it reaches the end of its life.
The Ear Protectors cost fifty pence each, for orders of two hundred. Contact the company direct for lower volume pricing.
For more information, visit: http://www.theearprotector.com
Patricia will take up the position at the start of November, replacing Mark Ross who is stepping down.
Patricia originally joined Vets Now in 2009, working in areas of hospital management and then business development.
She became COO in June 2021.
Patricia said today: “Vets Now is made up of fantastic people and it’s the honour of my career to be leading such a talented team.
“Our out-of-hours business model was set up twenty years ago by a vet to support the working practices of vets and vet nurses, helping to improve their work-life balance by providing outstanding animal care at times of greatest need to customers. As leaders in emergency care for small animals, we’ll continue to work steadfastly in supporting the profession.
“Mark has done a tremendous job driving the business forward and I’m excited to be able to continue to build on our success. “
Vets Now says it is working hard to drive diversity and inclusion within the profession, and with 88% of Vets Now staff being female, Patricia will lead a board of directors of whom nine out of ten are women.
That doesn't sound very diverse to me.
Where are the men?
The company has created a new waiting room board kit as a way for veterinary staff to remind owners of the importance of prompt diagnosis and management of dental disease.
Animalcare has also created a Pet Dental Health Month social media pack with content practices can use on their social media channels.
During the month, the company will be offering dental CPD and prizes for the most creative and engaging waiting room displays.
Will Peel, Animalcare Marketing Manager said: "According to the RVC's VetCompass data, periodontitis is the most common disease seen in cats and dogs however, it can often be difficult to identify and pet owners can often disregard the signs of dental problems, assuming that their pet’s bad breath is normal.
‘Our popular Lunch and Learn sessions have demonstrated to us that veterinary staff recognise the importance of raising dental health awareness, so we’ve created this range of materials specifically to support veterinary practices and their patients.’
The winners and runners up will be honoured at a ceremony taking place on the eve of BSAVA Congress on 3rd April 2019.
Matt Baker, presenter of The One Show and Countryfile, will be hosting the Ceva Animal Welfare Awards alongside the head judge, Chris Laurence MBE FRCVS, who puts his name to the Vet of the Year Award.
The award categories include:
Chris Laurence Vet of the Year – sponsored by Vet Record
Vet Nurse of the Year – sponsored by Agria Pet Insurance
Charity Team of the Year – sponsored by PDSA
Charitable Contribution of the Year – sponsored by Blue Cross
International Cat Care Welfare of the Year – sponsored by International Cat Care
Farmer of the Year – sponsored by R.A.B.I.
Farm Educator of the Year – sponsored by NADIS
Outstanding Contribution to Animal Welfare – sponsored by Your Dog and Your Cat magazines
To nominate someone for an award, visit www.cevawelfareawards.com. They can come from all walks of life and will be assessed on the evidence provided in the original nomination.
Entries must be in by Friday 25 January 2019.
The rationale for completing a course of antibiotics has always been to prevent the growth of drug-resistant bacteria. However, the article says there is little evidence to support this idea, and that in fact, taking antibiotics for longer than necessary presents a greater risk of causing antibiotic resistance.
Responding to article, BVA Junior Vice President John Fishwick said: "We're very aware of the global threat antimicrobial resistance poses to human and animal health, and the UK veterinary profession is committed to the responsible use of antibiotics. Medicines should never be used to compensate for poor husbandry practices and routine habitual prophylactic use in healthy animals to prevent disease is a no-go.
"The article in the BMJ suggests that antibiotics should be used for as short a period as possible, and that we should move away from the concept of following a predetermined course. This may indeed be a very important advance, but it is far too early to determine how this would work in veterinary practice. We need to clearly establish the evidence supporting it.
"We support the researchers’ calls for clinical trials to determine the most effective strategies for antibiotic treatment. Until further studies are conducted, it is too early to change the way we prescribe medicines and vets should continue to prescribe as previously, only when necessary. It is also vital that clients continue to follow the directions given by their vets, both in terms of dosage and duration of treatment, carefully."
Zoetis, formerly Pfizer Animal Health has launched Ovatec Plus, which it claims will make equine faecal collection and in-practice worm count testing quicker and easier.
Ovatec Plus is designed to facilitate the in-house detection of worm burdens by enabling the coproscopic examination of parasite eggs, larvae and cysts. Zoetis says the built-in sample collection scoop allows for hands-off, quick, clean sample collection and controlled sample size, while the built-in cap, which can be written on for easy identification, snaps shut to seals the contents safely for contamination-free transport.
The system is based on zinc sulphate flotation technology, with a flotation time of ten minutes to provide rapid analysis. The Ova-Spin feature will break up difficult samples. The positive-locking filter chamber prevents any spill of test samples and reduces operator exposure to potential hazards. The overflow reservoir prevents overfills leaking onto the lab bench.
Zoetis says the high sensitivity and excellent specificity of Ovatec Plus enable informed treatment decisions to be made. A study has shown that samples proving negative with Ovatec Plus provide 95% certainty that the sample is <150epg and 100% certainty that the sample is <250epg, which means treatment may not be necessary1. Samples that prove positive, with one or more eggs seen, can be verified using a quantitative technique if needed, alternatively treatment may be indicated.
Ben Lacey, equine business unit manager at Zoetis, said: "Ovatec Plus is an excellent addition to our equine worm control portfolio. It's ideal for use in many test situations, giving a quick, easy and convenient solution."
To find out more, speak to your Zoetis Account Manager, call 0845 300 8034 or email CustomerSupportUK@zoetis.com.
Reference
Zoetis has announced the launch of Simparica, a once-monthly oral medication for the treatment of flea, tick and mite infestations in dogs beginning at eight weeks of age.
The company says the new product, which comes in the form of a tasty chewable tablet, acts quickly and provides continuous protection for 35 days without losing efficacy at the end of the month.
Simparica is effective against both Ctenocephalides felis and Ctenocephalides canis flea infestations in dogs.² It starts to kill fleas quickly within three hours³ and continues to kill fleas for at least 35 days², making it suitable as part of a treatment strategy for Flea Allergic Dermatitis.
The product also protects dogs against infestations with the most common ticks found to infest dogs in Europe2,4, including Dermacentor reticulatus, the species associated with the disease babesiosis, which has recently been reported in the UK. It’s also the only treatment for Ixodes hexagonus, one of the most prevalent ticks in the UK. The killing effect against Ixodes ricinus starts within 8 hours after a single oral administration and over 96% are killed within 24 hours.4
Zoetis says Simparica is also effective against Rhipicephalus sanguineus, and Sarcoptes scabiei, and that laboratory evidence shows efficacy for Demodex Canis and Otodectes Cynotis.
Zoetis believes that Simparica’s ability to provide continuous protection up to and beyond the monthly treatment period is very important for pet owners. Sixty three per cent of owners confess to giving flea and tick treatment later than when it was due, with the median being 5 days late.¹ Simparica gives vets and forgetful pet owners the peace of mind of extended duration of activity helping to minimise the potential risk of protection gaps.
Ned Flaxman, companion animal business unit director at Zoetis said: "With Simparica, we bring to the market an advanced parasiticide solution, helping to deliver improved client and pet owner satisfaction. The chewable tablets are easy to administer and readily accepted by dogs. But more importantly, Simparica helps vets and dog owners minimise the potential risk of protection gaps, as it acts very fast to kill fleas and ticks and performs for at least 35 days without losing efficacy — well beyond the monthly treatment period.
"With its rapid onset, robust duration of activity and very good safety profile, Simparica is the only oral isoxazoline indicated for four species of ticks in Europe including Ixodes hexagonus and the two species of fleas, dogs are most frequently infested with. Unlike most treatments, Simparica protects from both types of ectoparasites for the same duration."
For more information please speak to your account manager or contact customer support on 0854 300 8034.
FirstVet says the funding will enable it to expand its service globally, including the United States, Germany, and France. It will also allow it to continue developing its product and introduce new features to improve the experience for pet owners and vets, such as new automation tools and integration with clinics' existing systems.
The latest round of financing takes FirstVet’s total funding to-date to €24.5M.
Founded in 2016 in Sweden, FirstVet currently has a presence in five markets: the United Kingdom, Norway, Denmark, Finland, and its native Sweden. The company says it has over 200,000 registered users and has provided consultations for over 150,000 pets since launch.
Currently, FirstVet consultations are offered free to millions of owners through partnerships with 20 insurance companies across all markets, including Bought By Many in the UK.
Co-founder David Prien said: "FirstVet is the first truly neutral stakeholder in the world to coordinate pet care. In what is a highly privatised industry, our reliable service provides value to the entire sector, and we are growing at an incredible rate."
The RCVS is inviting responses from veterinary surgeons, veterinary nurses and animal owners to a call for evidence on the provision of 24-hour emergency veterinary care, in order to understand how best to meet the expectations of all those involved.
In an open letter to the profession and the public published on the RCVS website, the Chairman of the RCVS Standards Committee, Clare Tapsfield-Wright, said:
"Over the past two years, lay people working with the RCVS have raised questions about the veterinary profession's ability to provide 24/7 to the extent required by the RCVS Code of Professional Conduct, and said there is a disconnect between the public's expectations and the profession's capacity to meet those expectations."
Clare also refers to an RCVS Disciplinary Committee Inquiry in June 2013, which raised a number of issues on home visits by veterinary surgeons, including: speed of response; travelling time and distance; daytime versus out-of-hours obligations; individual versus corporate responsibility; and, staffing levels and contingency plans.
The letter is accompanied by a range of background information, including the reports of Lay Observers to the RCVS Preliminary Investigation Committee; Working Party reports from the College's 2009 consultation on 24-hour emergency cover; and, further details about the June 2013 DC Inquiry.
The College says additional feedback will be sought through next year's RCVS Survey of the Professions, and via focus group research for animal owners. Once all responses have been collated, a number of individuals and organisations will be invited to a Standards Committee meeting to present and discuss their views.
Responses in writing are invited by 5pm on Monday, 17 February 2014, and should be emailed to 24-7@rcvs.org.uk or posted to the Professional Conduct Department, Royal College of Veterinary Surgeons, Belgravia House, 62-64 Horseferry Road, London SW1P 2AF.
Bayer Animal Health has launched Renalzin®, a feed additive for the management of Chronic Renal Disease (CRD), the leading cause of morbidity and mortality, especially in older cats1.
One-third of all cats over 15 years of age have CRD2, but the disease often remains undetected until the cat suddenly falls ill, by which stage 85% of kidney function may have already been lost3. The clinical signs are often subtle and non-specific, and diagnosis is complicated by the fact that changes in laboratory values occur relatively late in the disease.
Dr. Dennis Chew, specialist in veterinary urology and nephrology at the Ohio State University, said: "Most veterinary surgeons understand that CRD affects many cats, especially as they age, and is a leading cause of death. CRD is difficult to identify in early stages - early intervention with treatment can prevent progression of CRD to those with more serious kidney deficits. Restriction of dietary phosphorus intake is known to be a pivotal beneficial step in the stabilisation of CRD. Renalzin is a paste specifically formulated for cats that prevents dietary phosphate absorption across the intestine - a beneficial effect is gained when added to the cat's normal diet or to a veterinary renal diet".
The main ingredient of Renalzin is Bayer-registered Lantharenol® (lanthanum carbonate), a phosphate binder which binds to dietary phosphate within the gastrointestinal tract. According to the company, this renders it indigestible and thereby eases the burden on the already damaged kidneys.
Renalzin contains two additional ingredients - kaolin and vitamin E. Kaolin is a toxin binder which helps to reduce the absorption of toxins from the gastrointestinal tract. Vitamin E is known to reduce free radicals, improving immunity and protecting the integrity of cell membranes.
Bayer says that clinical studies demonstrate that Renalzin significantly increases faecal elimination and decreases urinary excretion of phosphorus 5. The product also decreases phosphate digestibility (absorption) in cats that are on both high and lower phosphate diets6. In addition, studies have shown that Renalzin causes a decrease in serum phosphate levels in cats with standard maintenance diets non-restricted in phosphorus7. Finally, a clinical trial in feline CRD patients revealed that taking Renalzin resulted in improvements in general clinical examination parameters as assessed by their veterinary surgeons over a two month period in cats on a normal diet7.
Renalzin comes in a pump applicator. One pump action provides 1 ml, with 2 ml being the recommended daily dose applied to and/or mixed with the cat's food. Having a neutral taste and being odourless, Renalzin® does not change the flavour of the cat's food and is flexible for clients to use as it can be given once or twice daily depending on the cat's feeding pattern.
References1 Lulich JP, O'Brien TD, Osbourne CA, Polzin DJ. Feline renal failure: questions, answers, questions. Cd Cont Ed Pract Vet 1992, 14(2): 127 - 151.2 Polzin DJ, Osbourne CA, Adams LG, Lulich JP. Medical management of feline chronic renal failure. In, Bonagura JD, Kirk RW (eds). Current Veterinarian Therapy X1. Philadelphia, PA, Saunders, 1992: 848-853.3 Grauer GF. Early detection of renal damage and disease in dogs and cats. Vet Clin Small Animal 2005, 35: 581-596.4 http://en.wikipedia.org/wiki/Lanthanum_carbonate.5 Schmidt B et al Bay 78-1887, J Vet Pharmacol Therap 2006, 29 (Suppl 1): 206-2076 Schmidt B, Spiecker-Hauser U, Gropp J. Effecrt of Lantharenol® on apparent phosphorus absorption from a conventional feline maintenance diet and a renal diet for cats. Proc Soc Nutr Physiol (2008) 17, in press.7 Data submitted for publication.
Virbac has announced the launch of Carprox Vet, a carprofen-based NSAID indicated for the alleviation of post-operative pain and inflammation following orthopaedic and soft tissue surgery in dogs and cats and for the treatment of chronic pain and inflammation in dogs.
Carprox is presented as a palatable tablet for dogs in three sizes - 20 mg, 50 mg and 100 mg. An injectable 50 mg/ml solution for dogs and cats has also been launched (in bottles of 20ml).
Virbac Marketing Manager for Companion Animals Simon Boulton MRCVS said: "We launched our meloxicam-based solution for acute and chronic pain, Inflacam, in 2013. With the arrival of Carprox Vet, we are now able to offer vets a carprofen-based alternative for added flexibility and choice. We are delighted to add it to our product range and are proud to say that Virbac now offers one of the widest ranges of products for the treatment of small animals in the UK."
Prevexxion RN is composed of a serotype-1 construct vaccine which Boehringer says offers a unique balance between safety and efficacy against the most virulent types of Marek’s disease virus strains.
Prevexxion RN+HVT+IBD is a solution combining Prevexxion RN and Vaxxitek HVT+IBD in one ampoule. It is designed to meet the needs of customers in long-life bird segments with protection from the hatchery.
Prevexxion RN vaccines are available in ampoules of 1000, 2000, and 4000 doses, frozen in liquid nitrogen.
Jerôme Baudon, Head of Poultry at Boehringer Ingelheim, said: “Our Prevexxion RN range provides value through innovation to Marek sensitive poultry producers looking for continuous live production productivity improvement and effective protection. Field and lab experiments conducted worldwide demonstrated its safety, efficacy and its strong, early, and long-lasting protection through the lifespan of the birds and against very virulent Marek’s disease challenge.
Prevexxion RN is the new golden standard for Marek's disease vaccination programs2”.
For more information, contact your Boehringer Ingelheim representative.